What do systematic reviews say?

Ketoconazole 400 mg vs Ketoconazole 200 mg

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  1 study (Scrimgeour 1985); no patient experienced oral candidiasis, not estimable
  1 study
  GRADE not reported

Thymostimulin vs placebo or no treatment

Thymostimulin showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.4 [0.12, 1.32]
  1 study · 35 participants
  GRADE not reported

Antifungal drugs partially absorbed from GI tract (miconazole, clotrimazole) vs placebo or no treatment

Antifungal drugs partially absorbed from GI tract (miconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.16 [0.06, 0.46]
  4 studies · 292 participants
  GRADE not reported

Nystatin vs Chlorhexidine plus nystatin

Nystatin showed no clear difference in oral candidiasis (present) compared with chlorhexidine plus nystatin; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.82 [0.73, 4.54]
  1 study · 50 participants
  GRADE not reported

Chlorhexidine vs Nystatin

Chlorhexidine showed no clear difference in oral candidiasis (present) compared with nystatin; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.89 [0.36, 2.21]
  1 study · 34 participants
  GRADE not reported

Nystatin vs placebo or no treatment

Nystatin showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.92 [0.78, 1.08]
  3 studies · 153 participants
  GRADE not reported

Nystatin vs Natamycin

Nystatin showed no clear difference in oral candidiasis (present) compared with natamycin; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.07 [0.83, 1.37]
  1 study · 28 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Antifungal drugs absorbed from GI tract led to lower oral candidiasis (present) compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.4 [0.21, 0.76]
  8 studies · 2103 participants
  GRADE not reported

Ketoconazole vs Itraconazole

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  1 study (Caselli 1990); no evidence of a difference; not estimable/not pooled
  1 study
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.47 [0.29, 0.78]
  7 studies · 1153 participants
  GRADE not reported

Colchicine (oral) vs placebo

Colchicine (oral) may leads to lower number of participants experiencing an attacka,b compared with placebo (low certainty).

• Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
  RR 0.21 [0.05, 0.95]
  1 study · 10 participants
  Low

Colchicine (oral) vs placebo

• Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 9 participants
  Very low

Colchicine (oral) vs placebo

• Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Very low

Colchicine (oral) vs placebo

The review found no eligible studies for this question.

• Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Colchicine (oral) vs placebo

It is very uncertain whether colchicine (oral) changes adverse drug reactions compared with placebo (very low certainty).

• Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Very low

Colchicine (oral) vs placebo

The review found no eligible studies for this question.

• Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral progesterone vs vaginal progesterone

The review found no eligible studies for this question.

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral progesterone vs vaginal progesterone

It is very uncertain whether oral progesterone changes ongoing pregnancy rate compared with vaginal progesterone (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 1.25 [0.7, 2.22]
  1 study · 150 participants
  Very low

Oral progesterone vs vaginal progesterone

It is very uncertain whether oral progesterone changes miscarriage rate per clinical pregnancy compared with vaginal progesterone (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 0.58 [0.11, 3.09]
  1 study · 41 participants
  Very low

Oral progesterone vs vaginal progesterone

It is very uncertain whether oral progesterone changes clinical pregnancy rate compared with vaginal progesterone (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 1.16 [0.69, 1.96]
  1 study · 150 participants
  Very low